Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.53 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.53 |
| ▸ | P2RY6 | Q15077 | 12/20 | 0.47 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.47 |
| ▸ | NT5E | P21589 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.34 |
| ▸ | P2RY2 | P41231 | 6/20 | 0.34 |
| ▸ | P2RY4 | P51582 | 5/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30177207 | 0.92 | ABL1 (0.52) | ABL1RIN1P2RY6P2RY14NT5E | |
| SCHEMBL15144425 | 0.92 | ABL1 (0.52) | ABL1RIN1P2RY6P2RY14NT5E | |
| SCHEMBL17589388 | 0.92 | ABL1 (0.52) | ABL1RIN1P2RY6P2RY14NT5E | |
| SCHEMBL27158019 | 0.88 | ABL1 (0.47) | ABL1RIN1P2RY6P2RY14NT5E | |
| SCHEMBL17589393 | 0.88 | ABL1 (0.48) | ABL1RIN1P2RY6P2RY14NT5E | |
| SCHEMBL27159489 | 0.88 | ABL1 (0.48) | ABL1RIN1P2RY6P2RY14NT5E | |
| SCHEMBL23607152 | 0.87 | ABL1 (0.56) | ABL1RIN1P2RY6P2RY14NT5E | |
| SCHEMBL30892888 | 0.86 | POLB (0.47) | ABL1RIN1P2RY6P2RY14NT5E | |
| SCHEMBL27158214 | 0.86 | ABL1 (0.59) | ABL1RIN1P2RY6P2RY14NT5E | |
| SCHEMBL29975237 | 0.85 | P2RY6 (0.49) | ABL1RIN1P2RY6P2RY14NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10415036-B2 | Morpholino oligonucleotide manufacturing method | AJINOMOTO CO., INC. (JP) | 2019-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10415036-B2 | Morpholino oligonucleotide manufacturing method | RNGTT, RNMT, NSUN2 | ABL1 3019/4885RIN1 4695/4885P2RY6 4328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.